GW Pharmaceuticals Ltd.
Porton Down Science Park
Salisbury
Wiltshire
SP4 0JQ
United Kingdom
Tel: 44-1980-619000
Fax: +44-1980-619111
Website: http://www.medicinal-cannabis.org/
Email: jdg@guy.org.uk
282 articles about GW Pharmaceuticals Ltd.
-
The acquisition of Sunosi transforms Axsome into a global commercial business that will support its operations as it moves closer to launching its treatments for depression and migraine.
-
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
-
Marijuana Legalization at the Federal Level Likely Needed to Open Up Medical Cannabis R&D Market
7/15/2021
Senator Charles Schumer unveiled draft legislation that would decriminalize cannabis and expunge federal sentences associated with the drug, but it likely faces an uphill battle. -
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
4/29/2021
GW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British business
-
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
4/23/2021
GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today.
-
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
4/20/2021
TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines
-
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting
4/13/2021
EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and safety results in patients with spasticity associated with multiple sclerosis
-
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex
2/26/2021
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX ® (cannabidiol) as an adjunctive treatment of seizures
-
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
2/16/2021
GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced financial results and operating progress for the fourth quarter and full-year ended December 31, 2020.
-
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
2/3/2021
Jazz Pharmaceuticals and GW Pharmaceuticals today announced the companies have entered into a definitive agreement for Jazz to acquire GW
-
Jazz Pharmaceuticals will beef up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.
-
GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
1/11/2021
- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year - - Total Epidiolex ® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year – - Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 - LONDON and CARLSBAD, Calif., Jan. 11, 2021
-
GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
GW Pharmaceuticals plc, the world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that Justin Gover, GW’s Chief Executive Officer, will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00 am PT.
-
CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
GW Pharmaceuticals plc, the world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that Justin Gover, GW’s Chief Executive Officer, will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00 am ET.
-
JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis ComplexEPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized
12/21/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results of the company’s positive Phase 3 clinical trial of EPIDIOLEX ® (cannabidiol) oral solution in seizures associated with tuberous sclerosis complex (TSC). EPIDI
-
GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
12/7/2020
GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that the Company will present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference on Thursday, December 10, 2020 at 11:00am EST.
-
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference
11/30/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Invest
-
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
11/9/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Inv